PRE-TESTING AND VACCINATION

For more detailed information on vaccinations, please see the CANIBD Vaccination Guide

TB skin test, blood work (baseline CBC, liver enzymes, lipids, CK, renal function, Hepatitis B serology)

Ensure all immunizations are current. Refer to CANIBD Vaccination Guidelines for further information.14

METHOD OF ADMINISTRATION

Infusion/injection

LOCATION

Infusion centre
Home

DOSING

Induction: 300 mg IV wks 0, 4 and 8,

Evaluate patients after 12-week induction dosing and if there is adequate response transition to maintenance dosing.

If patients do not have adequate therapeutic response at week 12 after induction dosing, consider extended induction dosing by administering 300 mg IV at weeks 12, 16, and 20.

Maintenance:
200 mg SC (2 consecutive injections of 100 mg each) at wk 12 and every 4 wks thereafter.

TIME REQUIRED

Minimum 30-min infusion

Self-injection 5 min

ROUTINE MONITORING

Evaluate liver enzymes and bilirubin at baseline and every 1–4 mos during induction (including induction period, if applicable) and thereafter according to standard practice.
Annual cervical cancer screening – pap test
Annual skin exam – skin malignancies
Influenza vaccine recommended
Screening for osteoporosis with bone mineral density testing periodically after diagnosis